Therapeutic effects of methionine sulfoximine in multiple diseases include and extend beyond inhibition of glutamine synthetase

References

• Ronzio RA, Rowe WB, Meister A. Studies on the mechanism of inhibition of glutamine synthetase by methionine sulfoximine. Biochemistry. 1969;8:1066–1075.
   PubMed Web of Science ®Google Scholar
• Rowe WB, Ronzio RA, Meister A. Inhibition of glutamine synthetase by methionine sulfoximine. Studies on methionine sulfoximine phosphate. Biochemistry. 1969;8:2674–2680.
   PubMed Web of Science ®Google Scholar
• Jeitner TM, Cooper AJ. Inhibition of human glutamine synthetase by L-methionine-S,R-sulfoximine-relevance to the treatment of neurological diseases. Metab Brain Dis. 2014;29:983–989.
   PubMed Web of Science ®Google Scholar
• Lamar C Jr. The duration of the inhibition of glutamine synthetase by methionine sulfoximine. Biochem Pharmacol. 1968;17:636–640.
   PubMed Web of Science ®Google Scholar
• Manning JM, Moore S, Rowe WB, et al. Identification of L-methionine S-sulfoximine as the diastereoisomer of L-methionine SR-sulfoximine that inhibits glutamine synthetase. Biochemistry. 1969;8:2681–2685.
   PubMed Web of Science ®Google Scholar
• Rowe WB, Meister A. Identification of L-methionine-S-sulfoximine as the convulsant isomer of methionine sulfoximine. Proc Natl Acad Sci USA. 1970;66:500–506.
   PubMed Web of Science ®Google Scholar
• Richman PG, Orlowski M, Meister A. Inhibition of gamma-glutamylcysteine synthetase by L-methionine-S-sulfoximine. J Biol Chem. 1973;248:6684–6690.
   PubMed Web of Science ®Google Scholar
• Cooper AJ. Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase. Metab Brain Dis. 2013;28:119–125.
   PubMed Web of Science ®Google Scholar
• Brusilow SW, Koehler RC, Traystman RJ, et al. Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics. 2010;7:452–470.
   PubMed Web of Science ®Google Scholar
• Haussinger D, Sies H. Hepatic encephalopathy: clinical aspects and pathogenetic concept. Arch Biochem Biophys. 2013;536:97–100.
   PubMed Web of Science ®Google Scholar
• Haussinger D, Kircheis G, Fischer R, et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol. 2000;32:1035–1038.
   PubMed Web of Science ®Google Scholar
• Gorg B, Schliess F, Haussinger D. Osmotic and oxidative/nitrosative stress in ammonia toxicity and hepatic encephalopathy. Arch Biochem Biophys. 2013;536:158–163.
   PubMed Web of Science ®Google Scholar
• Haussinger D, Laubenberger J. vom Dahl S, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 1994;107:1475–1480.
   PubMed Web of Science ®Google Scholar
• Lachmann V, Gorg B, Bidmon HJ, et al. Precipitants of hepatic encephalopathy induce rapid astrocyte swelling in an oxidative stress dependent manner. Arch Biochem Biophys. 2013;536:143–151.
   PubMed Web of Science ®Google Scholar
• Shah NJ, Neeb H, Kircheis G, et al. Quantitative cerebral water content mapping in hepatic encephalopathy. Neuroimage. 2008;41:706–717.
   PubMed Web of Science ®Google Scholar
• Ross BD, Jacobson S, Villamil F, et al. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology. 1994;193:457–463.
   PubMed Web of Science ®Google Scholar
• Cauli O, Llansola M, Agusti A, et al. Cerebral oedema is not responsible for motor or cognitive deficits in rats with hepatic encephalopathy. Liver Int. 2014;34:379–387.
   PubMed Web of Science ®Google Scholar
• Gilon E, Szeinberg A, Tauman G, et al. Glutamine estimation in cerebrospinal fluid in cases of liver cirrhosis and hepatic coma. J Lab Clin Med. 1959;53:714–719.
   PubMed Web of Science ®Google Scholar
• Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol. 1999;31:771–776.
   PubMed Web of Science ®Google Scholar
• Brusilow SW. Hyperammonemic encephalopathy. Medicine (Baltimore). 2002;81:240–249.
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Plum F. Biochemistry and physiology of brain ammonia. Physiol Rev. 1987;67:440–519.
   PubMed Web of Science ®Google Scholar
• Lavoie J, Giguere JF, Layrargues GP, et al. Activities of neuronal and astrocytic marker enzymes in autopsied brain tissue from patients with hepatic encephalopathy. Metab Brain Dis. 1987;2:283–290.
   PubMed Web of Science ®Google Scholar
• Record CO, Buxton B, Chase RA, et al. Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. Eur J Clin Invest. 1976;6:387–394.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Saraswat VA, Poptani H, et al. Magnetic resonance imaging and localized in vivo proton spectroscopy in patients with fulminant hepatic failure. Am J Gastroenterol. 1993;88:670–674.
   PubMed Web of Science ®Google Scholar
• Haseler LJ, Sibbitt WL Jr., Mojtahedzadeh HN, et al. Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during oral lactulose therapy. AJNR Am J Neuroradiol. 1998;19:1681–1686.
   PubMed Web of Science ®Google Scholar
• Tofteng F, Hauerberg J, Hansen BA, et al. Persistent arterial hyperammonemia increases the concentration of glutamine and alanine in the brain and correlates with intracranial pressure in patients with fulminant hepatic failure. J Cereb Blood Flow Metab. 2006;26:21–27.
   PubMed Web of Science ®Google Scholar
• Warren KS, Schenker S. Effect of an inhibitor of glutamine synthesis (methionine sulfoximine) on ammonia toxicity and metabolism. J Lab Clin Med. 1964;64:442–449.
   PubMed Web of Science ®Google Scholar
• Brusilow SW. Disorders of the urea cycle. Hosp Pract (Off Ed). 1985;20:65–72.
   PubMed Web of Science ®Google Scholar
• Brusilow SW, Traystman R. Hepatic encephalopathy. N Engl J Med. 1986;314:786–787. author reply 7.
   PubMed Web of Science ®Google Scholar
• Watson AJ, Chambers T, Karp JE, et al. Transient idiopathic hyperammonaemia in adults. Lancet. 1985;2:1271–1274.
   PubMed Web of Science ®Google Scholar
• Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology. 2006;44:788–794.
   PubMed Web of Science ®Google Scholar
• Rama Rao KV, Norenberg MD. Glutamine in the pathogenesis of hepatic encephalopathy: the Trojan horse hypothesis revisited. Neurochem Res. 2014;39:593–598.
   PubMed Web of Science ®Google Scholar
• Willard-Mack CL, Koehler RC, Hirata T, et al. Inhibition of glutamine synthetase reduces ammonia-induced astrocyte swelling in rat. Neuroscience. 1996;71:589–599.
   PubMed Web of Science ®Google Scholar
• Blei AT. The pathophysiology of brain edema in acute liver failure. Neurochem Int. 2005;47:71–77.
   PubMed Web of Science ®Google Scholar
• Blei AT, Olafsson S, Therrien G, et al. Ammonia-induced brain edema and intracranial hypertension in rats after portacaval anastomosis. Hepatology. 1994;19:1437–1444.
   PubMed Web of Science ®Google Scholar
• Hawkins RA, Jessy J, Mans AM, et al. Effect of reducing brain glutamine synthesis on metabolic symptoms of hepatic encephalopathy. J Neurochem. 1993;60:1000–1006.
   PubMed Web of Science ®Google Scholar
• Brusilow SW, Cooper AJ. Encephalopathy in acute liver failure resulting from acetaminophen intoxication: new observations with potential therapy. Crit Care Med. 2011;39:2550–2553.
   PubMed Web of Science ®Google Scholar
• Gorg B, Qvartskhava N, Bidmon HJ, et al. Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology. 2010;52:256–265.
   PubMed Web of Science ®Google Scholar
• Gorg B, Karababa A, Shafigullina A, et al. Ammonia-induced senescence in cultured rat astrocytes and in human cerebral cortex in hepatic encephalopathy. Glia. 2015;63:37–50.
   PubMed Web of Science ®Google Scholar
• Jordens MS, Keitel V, Karababa A, et al. Multidrug resistance-associated protein 4 expression in ammonia-treated cultured rat astrocytes and cerebral cortex of cirrhotic patients with hepatic encephalopathy. Glia. 2015;63:2092–2105.
   Web of Science ®Google Scholar
• Lewerenz J, Maher P. Chronic glutamate toxicity in neurodegenerative diseases – what is the evidence? Front Neurosci. 2015;9:469.
   PubMed Web of Science ®Google Scholar
• Martinez-Hernandez A, Bell KP, Norenberg MD. Glutamine synthetase: glial localization in brain. Science. 1977;195:1356–1358.
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Jeitner TM. Central role of glutamate metabolism in the maintenance of nitrogen homeostasis in normal and hyperammonemic brain. Biomolecules. 2016;6:16.
   Web of Science ®Google Scholar
• Broer S, Brookes N. Transfer of glutamine between astrocytes and neurons. J Neurochem. 2001;77:705–719.
   PubMed Web of Science ®Google Scholar
• Hertz L, Dringen R, Schousboe A, et al. Astrocytes: glutamate producers for neurons. J Neurosci Res. 1999;57:417–428.
   PubMed Web of Science ®Google Scholar
• Laake JH, Slyngstad TA, Haug FM, et al. Glutamine from glial cells is essential for the maintenance of the nerve terminal pool of glutamate: immunogold evidence from hippocampal slice cultures. J Neurochem. 1995;65:871–881.
   PubMed Web of Science ®Google Scholar
• Pow DV, Robinson SR. Glutamate in some retinal neurons is derived solely from glia. Neuroscience. 1994;60:355–366.
   PubMed Web of Science ®Google Scholar
• Ghoddoussi F, Galloway MP, Jambekar A, et al. Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and glutamate in a mouse model of ALS. J Neurol Sci. 2010;290:41–47.
   PubMed Web of Science ®Google Scholar
• Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26:438–458.
   PubMed Web of Science ®Google Scholar
• King AE, Woodhouse A, Kirkcaldie MT, et al. Excitotoxicity in ALS: overstimulation, or overreaction? Exp Neurol. 2016;275(Pt 1):162–171.
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39:147–157.
   PubMed Web of Science ®Google Scholar
• Swanson RA, Shiraishi K, Morton MT, et al. Methionine sulfoximine reduces cortical infarct size in rats after middle cerebral artery occlusion. Stroke. 1990;21:322–327.
   PubMed Web of Science ®Google Scholar
• Bame M, Pentiak PA, Needleman R, et al. Effect of sex on lifespan, disease progression, and the response to methionine sulfoximine in the SOD1 G93A mouse model for ALS. Gend Med. 2012;9:524–535.
   PubMedGoogle Scholar
• Bame M, Grier RE, Needleman R, et al. Amino acids as biomarkers in the SOD1(G93A) mouse model of ALS. Biochim Biophys Acta. 2014;1842:79–87.
   PubMed Web of Science ®Google Scholar
• Jambekar AA, Palma E, Nicolosi L, et al. A glutamine synthetase inhibitor increases survival and decreases cytokine response in a mouse model of acute liver failure. Liver Int. 2011;31:1209–1221.
   PubMed Web of Science ®Google Scholar
• Bode JG, Peters-Regehr T, Kubitz R, et al. Expression of glutamine synthetase in macrophages. J Histochem Cytochem. 2000;48:415–422.
   PubMed Web of Science ®Google Scholar
• Murphy C, Newsholme P. Macrophage-mediated lysis of a beta-cell line, tumour necrosis factor-alpha release from bacillus Calmette-Guerin (BCG)-activated murine macrophages and interleukin-8 release from human monocytes are dependent on extracellular glutamine concentration and glutamine metabolism. Clin Sci (Lond). 1999;96:89–97.
   PubMed Web of Science ®Google Scholar
• Rogero MM, Tirapegui J, Vinolo MA, et al. Dietary glutamine supplementation increases the activity of peritoneal macrophages and hemopoiesis in early-weaned mice inoculated with Mycobacterium bovis bacillus Calmette-Guerin. J Nutr. 2008;138:1343–1348.
   PubMed Web of Science ®Google Scholar
• Wells SM, Kew S, Yaqoob P, et al. Dietary glutamine enhances cytokine production by murine macrophages. Nutrition. 1999;15:881–884.
   PubMed Web of Science ®Google Scholar
• Palmieri EM, Menga A, Lebrun A, et al. Blockade of glutamine synthetase enhances inflammatory response in microglial cells. Antioxid Redox Signal. 2017;26:351–363.
   PubMed Web of Science ®Google Scholar
• Santos AC, Correia CA, de Oliveira DC, et al. Intravenous glutamine administration modulates TNF-alpha/IL-10 ratio and attenuates NFkB phosphorylation in a protein malnutrition model. Inflammation. 2016;39:1883–1891.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang X, Pan L, et al. Glutamine attenuates lipopolysaccharide-induced acute lung injury. Nutrition. 2009;25:692–698.
   PubMed Web of Science ®Google Scholar
• Sellinger OZ, Azcurra JM, Ohlsson WG. Methionine sulfoximine seizures. 8. The dissociation of the convulsant and glutamine synthetase inhibitory effects. J Pharmacol Exp Ther. 1968;164:212–222.
   PubMed Web of Science ®Google Scholar
• Sellinger OZ, Schatz RA, Porta R, et al. Brain methylation and epileptogenesis: the case of methionine sulfoximine. Ann Neurol. 1984;16(Suppl):S115–20.
   Google Scholar
• Gershoff SN, Elvehjem CA. The relative effect of methionine sulfoximine on different animal species. J Nutr. 1951;45:451–458.
   PubMed Web of Science ®Google Scholar
• Pollock GH. Species specificity of a gene toxicity. J Appl Physiol. 1949;1:802–806.
   PubMed Web of Science ®Google Scholar
• Boissonnet A, Hevor T, Cloix JF. Phenotypic differences between fast and slow methionine sulfoximine-inbred mice: seizures, anxiety, and glutamine synthetase. Epilepsy Res. 2012;98:25–34.
   PubMed Web of Science ®Google Scholar
• Blin M, Crusio WE, Hevor T, et al. Chronic inhibition of glutamine synthetase is not associated with impairment of learning and memory in mice. Brain Res Bull. 2002;57:11–15.
   PubMed Web of Science ®Google Scholar
• Krakoff IH. Effect of methionine sulfoximine in man. Clin Pharmacol Ther. 1961;2:599–604.
   PubMed Web of Science ®Google Scholar
• Bentley HR, Mc DE, Whitehead JK. Action of nitrogen trichloride on proteins; a synthesis of the toxic factor from methionine. Nature. 1950;165:735.
   PubMed Web of Science ®Google Scholar
• Proler M, Kellaway P. The methionine sulfoximine syndrome in the cat. Epilepsia. 1962;3:117–130.
   PubMed Web of Science ®Google Scholar
• Wada JA, Ikeda H. The susceptibility to auditory stimuli of animals treated with methionine sulfoximine. Exp Neurol. 1966;15:157–165.
   PubMed Web of Science ®Google Scholar
• Apostolakis M, Anogianakis G, Kallaras C, et al. Long-term effects of the administration of the convulsive substance DL-methionine-DL-sulfoximine to the rabbit. Brain Res Bull. 1989;23:257–262.
   PubMed Web of Science ®Google Scholar
• Berlicki L. Inhibitors of glutamine synthetase and their potential application in medicine. Mini Rev Med Chem. 2008;8:869–878.
   PubMed Web of Science ®Google Scholar
• Mowbray SL, Kathiravan MK, Pandey AA, et al. Inhibition of glutamine synthetase: a potential drug target in Mycobacterium tuberculosis. Molecules. 2014;19:13161–13176.
   PubMed Web of Science ®Google Scholar
• Hertz L, Zielke HR. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci. 2004;27:735–743.
   PubMed Web of Science ®Google Scholar
• Lee A, Lingwood BE, Bjorkman ST, et al. Rapid loss of glutamine synthetase from astrocytes in response to hypoxia: implications for excitotoxicity. J Chem Neuroanat. 2010;39:211–220.
   PubMed Web of Science ®Google Scholar
• Gorovits R, Avidan N, Avisar N, et al. Glutamine synthetase protects against neuronal degeneration in injured retinal tissue. Proc Natl Acad Sci USA. 1997;94:7024–7029.
   PubMed Web of Science ®Google Scholar
• Zhao X, Ahram A, Berman RF, et al. Early loss of astrocytes after experimental traumatic brain injury. Glia. 2003;44:140–152.
   PubMed Web of Science ®Google Scholar
• Zou J, Wang YX, Mu HJ, et al. Down-regulation of glutamine synthetase enhances migration of rat astrocytes after in vitro injury. Neurochem Int. 2011;58:404–413.
   PubMed Web of Science ®Google Scholar
• Crunelli V, Carmignoto G, Steinhauser C. Novel astrocyte targets: new avenues for the therapeutic treatment of epilepsy. Neuroscientist. 2015;21:62–83.
   PubMed Web of Science ®Google Scholar
• Loeppen S, Schneider D, Gaunitz F, et al. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res. 2002;62:5685–5688.
   PubMed Web of Science ®Google Scholar
• McCormick D, McQuaid S, McCusker C, et al. A study of glutamine synthetase in normal human brain and intracranial tumours. Neuropathol Appl Neurobiol. 1990;16:205–211.
   PubMed Web of Science ®Google Scholar
• Jayakumar AR, Norenberg MD. Glutamine synthetase: role in neurological disorders. Adv Neurobiol. 2016;13:327–350.
   PubMedGoogle Scholar
• Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;141:757–763.
   PubMed Web of Science ®Google Scholar
• Jabbari B. History of botulinum toxin treatment in movement disorders. Tremor Other Hyperkinet Mov (N Y). 2016;6:394.
   PubMed Web of Science ®Google Scholar
• Haussinger D, Sies H, Gerok W. Functional hepatocyte heterogeneity in ammonia metabolism. The intercellular glutamine cycle. J Hepatol. 1985;1:3–14.
   PubMed Web of Science ®Google Scholar